Olopatadine (nasal): Difference between revisions

Jump to navigation Jump to search
No edit summary
 
m (Protected "Olopatadine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(No difference)

Revision as of 18:57, 27 September 2011

Olopatadine (nasal)
Clinical data
Pregnancy
category
  • C
Routes of
administration
Ophthalmic
ATC code
Pharmacokinetic data
Elimination half-life3 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC21H23NO3
Molar mass337.412 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

WikiDoc Resources for Olopatadine (nasal)

Articles

Most recent articles on Olopatadine (nasal)

Most cited articles on Olopatadine (nasal)

Review articles on Olopatadine (nasal)

Articles on Olopatadine (nasal) in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Olopatadine (nasal)

Images of Olopatadine (nasal)

Photos of Olopatadine (nasal)

Podcasts & MP3s on Olopatadine (nasal)

Videos on Olopatadine (nasal)

Evidence Based Medicine

Cochrane Collaboration on Olopatadine (nasal)

Bandolier on Olopatadine (nasal)

TRIP on Olopatadine (nasal)

Clinical Trials

Ongoing Trials on Olopatadine (nasal) at Clinical Trials.gov

Trial results on Olopatadine (nasal)

Clinical Trials on Olopatadine (nasal) at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Olopatadine (nasal)

NICE Guidance on Olopatadine (nasal)

NHS PRODIGY Guidance

FDA on Olopatadine (nasal)

CDC on Olopatadine (nasal)

Books

Books on Olopatadine (nasal)

News

Olopatadine (nasal) in the news

Be alerted to news on Olopatadine (nasal)

News trends on Olopatadine (nasal)

Commentary

Blogs on Olopatadine (nasal)

Definitions

Definitions of Olopatadine (nasal)

Patient Resources / Community

Patient resources on Olopatadine (nasal)

Discussion groups on Olopatadine (nasal)

Patient Handouts on Olopatadine (nasal)

Directions to Hospitals Treating Olopatadine (nasal)

Risk calculators and risk factors for Olopatadine (nasal)

Healthcare Provider Resources

Symptoms of Olopatadine (nasal)

Causes & Risk Factors for Olopatadine (nasal)

Diagnostic studies for Olopatadine (nasal)

Treatment of Olopatadine (nasal)

Continuing Medical Education (CME)

CME Programs on Olopatadine (nasal)

International

Olopatadine (nasal) en Espanol

Olopatadine (nasal) en Francais

Business

Olopatadine (nasal) in the Marketplace

Patents on Olopatadine (nasal)

Experimental / Informatics

List of terms related to Olopatadine (nasal)

Overview

Olopatadine hydrochloride is an antihistamine and mast cell stabilizer, sold as a prescription eye drop (0.2% solution, trademark Pataday (or Patanol S in some countries), manufactured by Alcon). It is used to treat itching associated with allergic conjunctivitis (eye allergies). Olopatadine hydrochloride 0.1% is sold as trademark Patanol (or Opatanol in some countries).

It should not be used to treat irritation caused by contact lenses. The usual dose for trademark Pataday is 1 drop in each affected eye once a day. The usual dose for trademark Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses.

Its side effects may include headaches (7% of occurrence) burning and stinging (5%), dry eye, foreign body sensation, hyperemia, keratitis, lid edema, pruritus, asthenia, cold syndrome, pharyngitis, rhinitis, sinusitis, and taste change.

External links

Template:SIB Template:WH Template:WikiDoc Sources